Top 25 Translational Regenerative Medicine Manufacturers 2019

1. Report Overview

1.1 Overview of the Top Translational Regenerative Medicine Manufacturers

1.2 Why You Should Read This Report

1.3 How This Report Delivers

1.4 Main Questions Answered by This Analytical Study

1.5 Who is This Report For?

1.6 Methodology

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Visiongain Reports

1.9 About Visiongain

2. Translational Regenerative Medicine Market Landscape

2.1 Introduction to Translational Regenerative Medicine

2.1.1 What is Regenerative Medicine?

2.1.2 Translational Regenerative Medicine – From Bench to Bedside

2.1.3 Translational Regenerative Medicine Segments

2.2 Stem Cell Therapy Definition and Overview

2.2.1 How Embryonic Stem Cells (ESCs) Entered the Fray

2.2.2 Classifying Stem Cells by Potency

2.2.3 Stem Cells Categories: ESCs, SSCs, iPSCs

2.2.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?

2.2.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?

2.3 Tissue Engineering Definition and Overview

2.4 Gene Therapy Definition and Overview

2.4.1 Harnessing Infectivity: Viral Vectors in Gene Therapy

2.5 Other Approaches to Regenerative Medicine

2.5.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signalling Molecules

2.5.2 Cosmetic Applications of Regenerative Medicine

2.6 Regulation of Regenerative Medicine

2.6.1 Regulation of Regenerative Medicine Products in Europe

2.6.2 Regulation of Regenerative Medicine Products in the US

2.6.3 Regulation of Regenerative Medicine Products in Japan

2.6.4 Regulation of Regenerative Medicine Products in China

2.6.5 Regulation of Regenerative Medicine Products in Australia

2.6.6 Regulation of Regenerative Medicine Products in India

2.6.7 Regulation of Regenerative Medicine Products in Ireland

2.7 The Phases of Clinical Trials

2.8 Global Translational Regenerative Medicine: Market Overview & Market Revenue Forecast, 2018-2028

2.9 Market Dynamics

2.9.1 Driving and Restrictive Forces for Translational Regenerative Medicine Market, 2018

2.9.1.1 Market Driver:

2.9.1.1.1 Improvements in Regulatory Frameworks

2.9.1.1.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine

2.9.1.1.3 Strong Support from Governments in Multiple Regions

2.9.1.1.4 Increasing Ease of Product Commercialisation and Market Access

2.9.1.2 Market Restraints:

2.9.1.2.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth

2.9.1.2.2 Lack of Funding from Venture Capital

2.9.1.2.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing

2.9.1.2.4 Successful Commercialisation of TRM Products Requires New Business Models

2.9.2 Opportunity and Trends in Translational Regenerative Medicine Market, 2018

2.9.2.1 Market Opportunities:

2.9.2.1.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up

2.9.2.1.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth

2.9.2.1.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets

2.9.2.2 Market Threats:

2.9.2.2.1 Ethical Concerns Limiting R&D in Regenerative Medicine

2.9.2.2.2 Difficulty Establishing Evidence Base for Long-Term Efficacy of TRM Therapies

2.9.2.2.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth

2.9.2.2.4 Restraints on Reimbursement May Slow Growth

2.9.3 PESTEL Analysis for Global Translational Regenerative Medicine Market, 2018

2.9.3.1 Political

2.9.3.2 Economic

2.9.3.3 Social

2.9.3.4 Technological

2.9.3.5 Legal

2.9.3.6 Enviromental

2.9.4 Porter's Five Force Analysis for Global Translational Regenerative Medicine Market, 2018

2.9.4.1 Threat of New Entrants

2.9.4.2 Threat of Substitutes

2.9.4.3 Power of Suppliers

2.9.4.4 Power of Buyers

2.9.4.5 Rivalry among Competitors

3. Global Leading Translational Regenerative Medicine Products: Overview, 2018

3.1 Stem Cell Therapy

3.1.1 Cx601 (TiGenix)

3.1.2 NiCord (Gamida Cell Ltd.)

3.1.3 Osteocel Plus (NuVasive)

3.1.3.1 Osteocel Plus: Sales Forecast 2018-2028

3.2 Tissue Engineering

3.2.1 Apligraf (Organogenesis, Inc.)

3.2.1.1 Apligraf: Sales Forecast 2018-2028

3.2.2 Grafix (Osiris Therapeutics, Inc.)

3.2.2.1 Grafix: Sales Forecast 2018-2028

3.2.3 ReCell (Avita Medical)

3.2.3.1 ReCell (Avita Medical): Sales Forecast 2018-2028

3.3 Gene Therapy

3.3.1 RT-100 (AC6 Gene Transfer) (Renova Therapeutics)

3.3.2 OXB 201 (Oxford Biomedica Plc)

3.3.3 LUXTURNA (voretigene neparvovec) (Spark Therapeutics, Inc)



4. Leading Global Translational Regenerative Medicine Manufacturers, 2018

4.1 Translational Regenerative Medicine: Leading Companies

4.2 Alphatec Spine, Inc.

4.2.1 Alphatec Spine, Inc: Financial and Performance Analysis, 2012-2017

4.2.2 Alphatec Spine’s Shifting Focus from Regenerative Medicine to Medical Devices

4.2.3 Alphatec Spine, Inc: Revenue Forecast, 2018-2028

4.3 Anterogen Co Ltd.

4.3.1 Anterogen Co Ltd: Financial and Performance Analysis, 2014-2017

4.3.2 Anterogen Co Ltd: Regenerative Medicine Product Portfolio, 2017

4.3.3 Anterogen Co Ltd: Pipeline Analysis, 2017

4.3.4 Anterogen Co Ltd: Revenue Forecast, 2018-2028

4.4 Athersys Inc

4.4.1 Athersys Inc: Financial and Performance Analysis, 2012-2017 & Revenue Forecast, 2018-2028

4.4.2 Athersys Inc: Key Developments in Regenerative Medicine Segment

4.4.3 Athersys Inc: Pipeline Analysis, 2017

4.4.3.1 MultiStem Technology – Potential Treatment for a Range of Diseases

4.5 Avita Medical Ltd

4.5.1 Avita Medical Ltd: Financial and Performance Analysis, 2013-2017 & Revenue Forecast, 2018-2028

4.5.2 Avita Medical Ltd: Regenerative Medicine Portfolio, 2017

4.5.3 Avita Medical Ltd: Key Developments in Regenerative Medicine Segment

4.5.4 Avita Medical Ltd: Pipeline Analysis, 2017

4.6 AxoGen, Inc.

4.6.1 AxoGen, Inc: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.6.2 AxoGen, Inc: Regenerative Medicine Portfolio, 2017

4.6.3 AxoGen, Inc: Pipeline Analysis, 2017

4.7 Medipost, Co Ltd.

4.7.1 Medipost Co Ltd: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.7.2 Medipost Co Ltd: Regenerative Medicine Portfolio, 2017

4.7.3 Medipost Co Ltd: Pipeline Analysis, 2017

4.8 Mesoblast Ltd

4.8.1 Mesoblast, Ltd: Financial and Performance Analysis, 2012-2017 and Revenue Forecast, 2018-2028

4.8.2 Mesoblast, Ltd Product Portfolio, 2017

4.8.3 Mesoblast, Ltd: Pipeline Analysis, 2017

4.8.3.1 NeoFuse

4.8.3.2 Chondrogen

4.8.3.3 Prochymal / TEMCELL

4.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast

4.9 NuVasive, Inc

4.9.1 NuVasive, Inc: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.9.2 NuVasive, Inc Product Portfolio, 2017

4.9.3 NuVasive: Pipeline Analysis, 2017

4.10 BioTime, Inc.

4.10.1 Biotime, Inc: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.10.2 BioTime, Inc: Regenerative Medicine Product Portfolio, 2017

4.10.3 BioTime, Inc: Key Developments in Regenerative Medicine Segment

4.10.4 BioTime, Inc: Pipeline Analysis, 2018

4.11 Organogenesis

4.11.1 Organogenesis, Inc: Regenerative Medicine Portfolio, 2017

4.11.2 Organogenesis, Inc: Key Developments in Regenerative Medicine Segment

4.11.3 Organogenesis, Inc: Pipeline Analysis, 2017

4.12 Pharmicell, Co Ltd.

4.12.1 Pharmicell, Co Ltd: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.12.2 Pharmicell, Co Ltd: Pipeline Analysis, 2017

4.13 Regenerys, Ltd

4.13.1 Regenerys, Ltd: Regenerative Medicine Portfolio, 2017

4.13.2 Regenerys: Pipeline Analysis, 2017

4.14 TiGenix

4.14.1 TiGenix NV: Regenerative Medicine Product Portfolio, 2017

4.14.2 TiGenix NV: Key Developments in Regenerative Medicine Segment

4.14.3 TiGenix: Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.14.4 TiGenix: Pipeline Analysis, 2017

4.15 UniQure

4.15.1 Uniqure: Regenerative Medicine Product Portfolio, 2017

4.15.2 Uniqure: Financial and Performance Analysis, 2015-2017 and Revenue Forecast, 2018-2028

4.15.3 UniQure: Recent Major Acquisition and Collaboration

4.15.4 UniQure: Pipeline Analysis, 2017

4.16 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)

4.16.1 Vericel Corporation: Regenerative Medicine Portfolio, 2017

4.16.2 Vericel’s Acquisition of Sanofi’s Regenerative Medicine Business

4.16.3 Vericel Corporation: Historical Financial and Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.16.4 Vericel Corporation: Pipeline Analysis, 2017

4.16.4.1 The ixCELL-DCM Clinical Trial

4.17 Anika Therapeutics, Inc.

4.17.1 Anika Therapeutics, Inc: Regenerative Medicine Product Portfolio, 2017

4.17.2 Anika Therapeutics, Inc: Key Developments in Regenerative Medicine Segment

4.17.3 Anika Therapeutics, Inc: Historical Financial & Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.17.4 Anika Therapeutics, Inc: Pipeline Analysis, 2017

4.18 Orthofix International, Inc.

4.18.1 Orthofix International, Inc: Regenerative Medicine Product Portfolio, 2017

4.18.2 Orthofix International, Inc: Key Developments in Regenerative Medicine Segment

4.18.3 Orthofix International, Inc: Historical Financial & Performance Analysis, 2012-2017 and Revenue Forecast, 2018-2028

4.18.4 Orthofix International, Inc: Pipeline Analysis, 2017

4.19 Medtronic, Plc.

4.19.1 Medtronic, Plc: Product Portfolio, 2017

4.19.2 Medtronic, Plc: Key Developments in Regenerative Medicine Segment

4.19.3 Medtronic, Plc: Historical Financial & Performance Analysis, 2015-2017 and Revenue Forecast 2018-2028

4.19.4 Medtronic, Plc: Pipeline Analysis, 2017

4.20 Stryker Corporation

4.20.1 Stryker Corporation: Regenerative Medicine Product Portfolio, 2017

4.20.2 Stryker Corporation: Key Developments in Regenerative Medicine Segment

4.20.3 Stryker Corporation: Historical Financial & Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.21 Acelity, Inc.

4.21.1 Acelity, Inc: Regenerative Medicine Product Portfolio, 2017

4.21.2 Acelity, Inc: Key Developments in Regenerative Medicine Segment

4.21.3 Acelity, Inc: Historical Financial & Performance Analysis, 2011-2015 and Revenue Forecast, 2018-2028

4.22 Brainstorm Cell Therapeutics, Inc.

4.22.1 Brainstorm Cell Therapeutics, Inc: Regenerative Medicine Product Portfolio, 2017

4.22.2 Brainstorm Cell Therapeutics, Inc: Key Developments in Regenerative Medicine Segment

4.22.3 Brainstorm Cell Therapeutics, Inc: Historical Financial & Performance Analysis, 2015-2017

4.22.4 Brainstorm Cell Therapeutics, Inc: Pipeline Analysis, 2017

4.23 Integra Lifesciences.

4.23.1 Integra Lifesciences: Regenerative Medicine Product Portfolio, 2017

4.23.2 Integra Lifesciences: Key Developments in Regenerative Medicine Segment

4.23.3 Integra Lifesciences: Historical Financial & Performance Analysis, 2013-2017 and Revenue Forecast, 2018-2028

4.24 Sangamo Therapeutics, Inc

4.24.1 Sangamo Therapeutics, Inc: Regenerative Medicine Product Portfolio, 2017

4.24.2 Sangamo Therapeutics, Inc: Key Developments in Regenerative Medicine Segment

4.24.3 Sangamo Therapeutics, Inc: Historical Financial & Performance Analysis, 2015-2017 and Revenue Forecast, 2018-2028

4.24.4 Sangamo Therapeutics, Inc: Pipeline Analysis, 2017

4.25 Japan Tissue Engineering, Co Ltd (J-Tec)

4.25.1 Japan Tissue Engineering, Co Ltd: Regenerative Medicine Product Portfolio, 2017

4.25.2 Japan Tissue Engineering, Co Ltd: Key Developments in Regenerative Medicine Segment

4.25.3 Japan Tissue Engineering, Co Ltd: Historical Financial & Performance Analysis, 2014-2017 and Revenue Forecast, 2018-2028

4.25.4 Japan Tissue Engineering, Co Ltd: Pipeline Analysis, 2017

4.26 Cytori Therapeutics, Inc.

4.26.1 Cytori Therapeutics, Inc: Regenerative Medicine Product Portfolio, 2017

4.26.2 Cytori Therapeutics, Inc: Key Developments In Regenerative Medicine Segment

4.26.3 Cytori Therapeutics, Inc: Historical Financial & Performance Analysis, 2015-2017 and Revenue Forecast, 2018-2028

4.26.4 Cytori Therapeutics, Inc: Pipeline Analysis, 2017

5. Conclusion

5.1 Overview of Current Market Competition and Competitor Forecast, 2018-2028

5.2 Leading Regenerative Medicine Players in 2017 and 2018

5.2.1 Acelity, Inc

5.2.2 Organogenesis Inc

5.2.3 Uniqure

5.2.4 TiGenix NV

5.2.5 Vericel Corporation

5.3 Future Outlook of Top 10 TRM competitors, 2018-2028

5.3.1 Medtronic PLC

5.3.2 Acelity

5.3.3 Integra Lifesciences

5.3.4 NuVasive, Inc

5.3.5 Orthofix International NV

5.3.6 Anika Therapeutics, Inc

5.3.7 Organogenesis

5.3.8 Uniqure

5.3.9 TiGenix NV

5.3.10 Vericel Corporation

5.3.11 R&D Pipeline Products Crucial to Future Market Growth

5.4 What Does the Future Hold for Regenerative Medicine?

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

List of Tables

Table 2.1 European Union Definitions of Regenerative Medicine Products, 2018

Table 2.2 Potency and Source of Stem Cells, 2018

Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2018

Table 2.4 Major Types of Stem Cells and Their Properties, 2018

Table 2.5 Terminology for Stem Cell Donor-Types, 2018

Table 2.6 Clinical Trial Phases, 2018

Table 2.7 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2017-2022

Table 2.8 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2023-2028

Table 2.9 SWOT Analysis of the Global Translational Regenerative Medicine Market, 2018-2028

Table 3.1 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022

Table 3.2 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028

Table 3.3 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022

Table 3.4 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028

Table 3.5 Grafix/Stravix Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022

Table 3.6 Grafix/Stravix Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028

Table 3.7 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2022

Table 3.8 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2023-2028

Table 4.1 Alphatec Spine Details, 2018

Table 4.2 Alphatec Spine, Inc: Historical Sales ($m) and Operating Profit / Loss ($m), 2012-2017

Table 4.3 Alphatec Spine: Regenerative Medicine Clinical Trials, 2017

Table 4.4 Forecast Alphatec Spine: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.5 Anterogen Co Ltd Details, 2018

Table 4.6 Anterogen Co Ltd: Historical Sales ($m) and Operating Profit / Loss ($m), 2014-2017

Table 4.7 Anterogen: Regenerative Medicine Clinical Trials, 2017

Table 4.8 Forecast Anterogen: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.9 Athersys Inc, Details, 2018

Table 4.10 Athersys Inc: Historical Sales ($m) 2012-2017

Table 4.11 Athersys Inc: Historical Expenditure and Losses ($m) 2012-2017

Table 4.12 Forecast Athersys Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.13 Athersys Inc: Regenerative Medicine Clinical Trials, 2018

Table 4.14 Avita Medical Ltd Details, 2018

Table 4.15 Avita Medical Ltd: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2017

Table 4.16 Forecast Avita Medical Ltd: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.17 Avita Medical: Regenerative Medicine Clinical Trials, 2017

Table 4.18 AxoGen Inc. Details, 2018

Table 4.19 AxoGen, Inc: Historical Sales ($m) and Net Loss ($m), 2013-2017

Table 4.20 Forecast AxoGen, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.21 AxoGen, Inc: Regenerative Medicine Clinical Trials, 2017

Table 4.22 Medipost Co Ltd Details, 2018

Table 4.23 Medipost: Historical Sales ($m, mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2013-2017

Table 4.24 Medipost: Historical Sales (mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2013-2017

Table 4.25 Forecast Medipost: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.26 Medipost: Regenerative Medicine Clinical Trials, 2017

Table 4.27 Mesoblast Ltd Details, 2018

Table 4.28 Mesoblast: Historical Sales ($m, AUD m), 2012-2017

Table 4.29 Forecast Mesoblast: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.30 Mesoblast: Regenerative Medicine Clinical Trials, 2017

Table 4.31 Nuvasive, Inc Details, 2018

Table 4.32 NuVasive, Inc: Historical Sales ($m) and Net Income (Profits and Losses) ($m), 2013-2017

Table 4.33 Forecast NuVasive, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.34 NuVasive: Regenerative Medicine Clinical Trials, 2017

Table 4.35 BioTime, Inc Details, 2018

Table 4.36 BioTime Inc: Historical Sales ($m) and Gross Income ($m), 2013-2017

Table 4.37 Forecast BioTime Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.38 Biotime, Inc: Regenerative Medicine Clinical Trials, 2018

Table 4.39 Organogenesis Inc, Details, 2018

Table 4.40 Organogenesis: Regenerative Medicine Clinical Trials, 2018

Table 4.41 Pharmicell, Co Ltd, Details, 2018

Table 4.42 Pharmicell: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2013-2016

Table 4.43 Forecast Pharmicell: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.44 Pharmicell Regenerative Medicine Trails, 2017

Table 4.45 Regenerys, Ltd Details, 2018

Table 4.46 Regenerys: Regenerative Medicine Clinical Trials, 2017

Table 4.47 TiGenix NV, Details, 2018

Table 4.48 TiGenix: Historical Sales (€m, $m) and Net Income (€m, $m), 2013-2017

Table 4.49 Forecast TiGenix: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.50 TiGenix: Regenerative Medicine Clinical Trials, 2017

Table 4.51 Uniqure Details, 2018

Table 4.52 Uniqure: Historical Sales ($m) and Operating Profit / Loss ($m), 2015-2017

Table 3.53 Forecast Uniqure: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.54 UniQure: Regenerative Medicine Clinical Trials, 2018

Table 4.55 Vericel Corporation, Details, 2018

Table 4.56 Vericel: Sales by Product ($m) and Revenue Share (%), 2016-2017

Table 4.57 Vericel: Historical Sales ($m and AGR%), 2013-2017

Table 3.58 Forecast Vericel: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.59 Vericel Corporation: Regenerative Medicine Clinical Trials, 2017

Table 4.60 Anika Therapeutics, Inc; Details, 2018

Table 4.61 Anika Therapeutics, Inc: Financial & Performance Analysis, 2013-2017

Table 4.62 Anika Therapeutics, Inc: Product Revenue Analysis, ($ Million) 2016-2017

Table 4.63 Forecast Anika Therapeutics, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.64 Orthofix International, Inc; Details, 2018

Table 4.65 Orthofix International, Inc: Financial & Performance Analysis, 2012-2017

Table 4.66 Orthofix International, Inc: Business Units Revenue Analysis, 2014- 2016

Table 4.67 Orthofix International, Inc: Business Units Revenue Analysis, 2016

Table 4.68 Forecast Orthofix International, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.69 Orthofix International, Inc: Regenerative Medicine Clinical Trials, 2017

Table 4.70 Medtronic, Plc; Details, 2017

Table 4.71 Medtronic, Plc: Financial & Performance Analysis, 2012-2017

Table 4.72 Medtronic, Plc: Divisional Revenue Analysis, 2014-2017

Table 4.73 Forecast Medtronic, Plc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.74 Stryker Corporation; Details, 2018

Table 4.75 Stryker Corporation: Financial & Performance Analysis, 2013-2017

Table 4.76 Forecast Stryker Corporation: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.77 Acelity, Inc; Details, 2018

Table 4.78 Acelity, Inc: Financial & Performance Analysis, 2011-2015

Table 4.79 Forecast Acelity, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.80 Brainstorm Cell Therapeutics, Inc; Details, 2018

Table 4.81 Brainstorm Cell Therapeutics, Inc: Financial & Performance Analysis, 2015-2017

Table 4.82 Brainstorm Cell Therapeutics, Inc: Pipeline Development of NurOwn product for different diseases

Table 4.83 Integra Lifesciences; Details, 2018

Table 4.84 Integra Lifesciences: Financial & Performance Analysis, 2013-2017

Table 4.85 Integra Lifesciences: Business Segment Revenue Analysis, 2015-2017

Table 4.86 Forecast Integra Lifesciences: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.87 Integra Lifesciences: Regenerative Medicine Clinical Trials, 2017

Table 4.88 Sangamo Therapeutics, Inc; Details, 2018

Table 4.89 Sangamo Therapeutics, Inc: Financial & Performance Analysis, 2013-2017

Table 4.90 Forecast Sangamo Therapeutics, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.91 Sangamo Therapeutics: Regenerative Medicine Clinical Trials, 2017

Table 4.92 Japan Tissue Engineering, Co Ltd; Details, 2018

Table 4.93 Japan Tissue Engineering, Co Ltd: Financial & Performance Analysis, 2014-2018

Table 4.94 Forecast Japan Tissue Engineering, Co Ltd: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 4.95 Cytori Therapeutics, Inc; Details, 2018

Table 4.96 Cytori Therapeutics, Inc: Financial & Performance Analysis, 2012-2017

Table 4.97 Forecast Cytori Therapeutics, Inc: Revenue ($m), Annual Growth (%), CAGR (%), 2017-2028

Table 5.1 Top Five TRM Manufacturers: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017

Table 5.2 TRM Manufacturers by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2012-2017

Table 5.3 Top 5 TRM Manufacturers ($m): Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027

Table 5.4 Top TRM Manufacturers by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2017-2022

Table 5.5 Top TRM Manufacturers by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2023-2028

Table 5.6 Global Translational Regenerative Medicine Market: Products in Late Stage Development, 2018

List of Figures

Figure 2.1 European Union Definitions of Regenerative Medicine Products, 2018

Figure 2.2 Examples of FDA-Approved Tissue Engineering Products

Figure 2.3 Brief History of Gene Therapy, 1970-2018

Figure 2.4 The Global Translational Regenerative Medicine Market Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 2.5 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2018

Figure 3.1 Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 3.2 Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 3.3 Grafix/Stravix Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 3.4 ReCell Sales Forecast: Revenue ($m) and AGR (%), 2017-2028

Figure 4.1 Alphatec Spine, Inc: Historical Sales ($m) and Operating Loss ($m), 2012-2017

Figure 4.2 Forecast Alphatec Spine: Revenue ($m), 2017-2028

Figure 4.3 Anterogen Co Ltd: Historical Sales ($ Thousand) and Operating Loss ($ Thousand), 2014-2017

Figure 4.4 Forecast Anterogen: Revenue ($m), 2017-2028

Figure 4.5 Athersys Inc: Historical Sales ($m) 2012-2017

Figure 4.6 Athersys Inc: Historical Revenue, Expenditure and Losses ($m) 2012-2017

Figure 4.7 Forecast Athersys Inc: Revenue ($m), 2017-2028

Figure 4.8 Avita Medical Ltd: Historical Sales ($m, AUD m) and Net Loss ($m), 2013-2017

Figure 4.9 Forecast Avita Medical Ltd: Revenue ($m), 2017-2028

Figure 4.10 AxoGen, Inc: Historical Sales ($m) and Net Loss ($m), 2013-2017

Figure 4.11 Forecast AxoGen, Inc: Revenue ($m), 2017-2028

Figure 4.12 Medipost Co Ltd: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2013-2017

Figure 4.13 Medipost: Revenue Share by Business Area (%), 2014

Figure 4.14 Medipost: Revenue Share by Business Area (%), 2015

Figure 4.15 Medipost: Revenue Share by Business Area (%), 2016

Figure 4.16 Medipost: Revenue Share by Business Area (%), 2017

Figure 4.17 Forecast AxoGen, Inc: Revenue ($m), 2017-2028

Figure 4.18 Mesoblast: Historical Sales (AUD m), 2013-2017

Figure 4.19 Forecast Mesoblast: Revenue ($m), 2017-2028

Figure 4.20 NuVasive, Inc: Historical Sales and Net Income (Profits and Losses) ($m), 2013-2017

Figure 4.21 Forecast NuVasive, Inc: Revenue ($m), 2017-2028

Figure 4.22 BioTime Inc: Historical Sales ($m) and Gross Income ($m), 2013-2017

Figure 4.23 Forecast BioTime Inc: Revenue ($m), 2017-2028

Figure 4.24 Pharmicell: Historical Sales (mil.KRW) and Net Income (mil.KRW), 2013-2017

Figure 4.25 Forecast Pharmicell: Revenue ($m), 2017-2028

Figure 4.26 TiGenix: Historical Sales ($m) and Net Income ($m), 2013-2017

Figure 4.27 Forecast TiGenix: Revenue ($m), 2017-2028

Figure 4.28 Uniqure: Sales ($m) and Operating Loss (In Thousands), 2015-2017

Figure 4.29 Forecast AxoGen, Inc: Revenue ($m), 2017-2028

Figure 4.30 Vericel: Revenue Contribution by Product (%) 2017

Figure 4.31 Vericel: Historical Sales ($m), 2013-2017

Figure 4.32 Forecast Vericel: Revenue ($m), 2017-2028

Figure 4.33 Anika Therapeutics, Inc: Financial & Performance Analysis, 2013-2017

Figure 4.34 Forecast Anika Therapeutics, Inc: Revenue ($m), 2017-2028

Figure 4.35 Orthofix International, Inc: Financial & Performance Analysis, 2012-2017

Figure 4.36 Orthofix International, Inc: Business Units Revenue Analysis, 2016

Figure 4.37 Forecast Orthofix International, Inc: Revenue ($m), 2017-2028

Figure 4.38 Medtronic Plc: Business Segment Revenue Analysis, 2017

Figure 4.39 Medtronic, Plc: Financial & Performance Analysis, 2012-2017

Figure 4.40 Medtronic, Plc: Divisional Revenue Analysis, 2014-2017

Figure 4.41 Forecast Medtronic, Plc: Revenue ($m), 2017-2028

Figure 4.42 Stryker Corporation: Financial & Performance Analysis, 2012-2017

Figure 4.43 Stryker Corporation: Business Segment Revenue Analysis, 2017

Figure 4.44 Forecast Stryker Corporation: Revenue ($m), 2017-2028

Figure 4.45 Acelity, Inc: Financial & Performance Analysis, 2011-2015

Figure 4.46 Forecast Acelity, Inc: Revenue ($m), 2017-2028

Figure 4.47 Brainstorm Cell Therapeutics, Inc: Financial & Performance Analysis, 2012-2017

Figure 4.48 Integra Lifesciences: Financial & Performance Analysis, 2013-2017

Figure 4.49 Integra Lifesciences: Business Segment Revenue Analysis, 2017

Figure 4.50 Forecast Integra Lifesciences: Revenue ($m), 2017-2028

Figure 4.51 Sangamo Therapeutics, Inc: Financial & Performance Analysis, 2013-2017

Figure 4.52 Forecast AxoGen, Inc: Revenue ($m), 2017-2028

Figure 4.53 Japan Tissue Engineering, Co Ltd: Financial & Performance Analysis, 2014-2018

Figure 4.54 Forecast Japan Tissue Engineering, Co Ltd: Revenue ($m), 2017-2028

Figure 4.55 Cytori Therapeutics, Inc: Financial & Performance Analysis, 2012-2017

Figure 4.56 Forecast Cytori Therapeutics, Inc: Revenue ($m), 2017-2028

Figure 5.1 Top Five TRM Manufacturers: Grouped Revenue ($m), 2012-2017

Figure 5.2 TRM Manufacturers by Absolute Change in Revenue ($m): Absolute Change in Revenue ($m), 2012-2017

Figure 5.3 Top 5 TRM Manufacturers: Grouped Revenue ($m), 2017-2028

Figure 5.4 Top TRM Manufacturers by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2017-2022

Figure 5.5 Top TRM Manufacturers by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2023-2028